ESR1 and breast cancer: PROTAC-2, PROTAC-B, compound 24, compound 11, and estrogen receptor degrader (ERD)-148, among other PROTACs, have been designed to induce the reduction of ERα levels in BC cells (Figure 3) [99–101].